<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97397">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830257</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-7</org_study_id>
    <nct_id>NCT01830257</nct_id>
  </id_info>
  <brief_title>Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)</brief_title>
  <acronym>AEFI</acronym>
  <official_title>Phase 4 Study of MR and APDT Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would remind the guardians of observation after immunization via sending
      short message and collect the information of AEFI by two ways, short message/telephone and
      website questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will compare the rate between active and inactive surveillance of AEFI
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence about AEFI</measure>
    <time_frame>1.5years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence about AEFI comes from the rate between number of adverse event and the all quantity for immunization about MR and APDT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adverse Reaction to Drug</condition>
  <arm_group>
    <arm_group_label>sending message</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators would send the tip to the children's guardian</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sending message</intervention_name>
    <description>Sending the suggestive short message</description>
    <arm_group_label>sending message</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  According with the regular vaccination

          -  Immunization the acellular pertussis diphtheria tetanus vaccine and Measles and
             rubella combined vaccine

        Exclusion Criteria:

          -  Disapproval the AEFI information
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoyun Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang District Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>March 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Drug Toxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
